Rimegepant + Placebo Comparator + Standard of Care + Rimegepant
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Menstrual Migraine
Conditions
Menstrual Migraine
Trial Timeline
Mar 11, 2025 → Mar 30, 2027
NCT ID
NCT06641466About Rimegepant + Placebo Comparator + Standard of Care + Rimegepant
Rimegepant + Placebo Comparator + Standard of Care + Rimegepant is a phase 3 stage product being developed by Pfizer for Menstrual Migraine. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06641466. Target conditions include Menstrual Migraine.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06641466 | Phase 3 | Recruiting |
Competing Products
11 competing products in Menstrual Migraine
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Elagolix + Estradiol /norethindrone acetate (E2/NETA) | AbbVie | Phase 3 | 77 |
| Atogepant + Placebo for Atogepant | AbbVie | Phase 3 | 77 |
| Marvelon | Merck | Approved | 85 |
| paroxetine | Novo Nordisk | Approved | 84 |
| Levonorgestrel/Ethinyl Estradiol | Pfizer | Phase 3 | 76 |
| Levonorgestrel/Ethinyl Estradiol | Pfizer | Phase 3 | 76 |
| Levetiracetam | UCB | Pre-clinical | 20 |
| Drospirenone and ethinyl estradiol + Placebo | Bayer | Pre-clinical | 20 |
| EE20/DRSP(YAZ, BAY86-5300) + Placebo | Bayer | Phase 3 | 74 |
| Vilaprisan (BAY1002670) | Bayer | Phase 3 | 74 |
| Etonogestrel 68mg implant | Organon | Phase 1 | 28 |